WASHINGTON, 2 February 2026 — Medical equipment maker Revvity reported a strong fourth-quarter performance and forecast 2026 revenue and profit above Wall Street expectations, banking on continued momentum in its diagnostics business despite ongoing weakness in academic research funding.
Life sciences companies have benefited from improving conditions in the pharmaceutical sector and easing policy uncertainty, helping to offset softer spending by universities and research institutions.
Revvity said it now expects adjusted profit per share of US$5.35 to US$5.45 in 2026, compared with analysts’ estimates of US$5.32, according to data compiled by LSEG. The company also forecast annual revenue of US$2.96 billion to US$2.99 billion, above analysts’ expectations of US$2.93 billion.
“We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations,” chief executive Prahlad Singh said.
Industry peers Danaher and Thermo Fisher Scientific also reported better-than-expected fourth-quarter results last week, underscoring a broader recovery across parts of the life sciences sector.
Revvity’s diagnostics unit, which provides testing tools for applications such as genetic screening, was a standout performer in the quarter ended December 28, delivering 7% organic growth and revenue of US$390.1 million, well above analysts’ estimates of US$377.7 million.
Meanwhile, the company’s life sciences unit, which sells reagents and instruments used in drug discovery, recorded quarterly revenue of US$382 million, slightly below analysts’ expectations of US$385.6 million.
On the bottom line, Revvity posted adjusted profit of US$1.70 per share for the quarter, comfortably beating estimates of US$1.55 per share. Quarterly revenue totalled US$772.1 million, also ahead of expectations of US$761.3 million.
